Haleon plc income statement
In fiscal 2025, Haleon plc reported revenue of $14.55bn, up 1.3% on the year before, operating income of $3.18bn (a 21.9% margin) and net income of $2.20bn, or $0.49 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 12.7 | 13.1 | 13.4 | 14.1 | 14.4 | 14.6 |
| Cost of revenue | 5.1 | 4.9 | 5.3 | 5.7 | 5.6 | 5.2 |
| Gross profit | 7.6 | 8.2 | 8.1 | 8.4 | 8.7 | 9.3 |
| Research and development | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
| Selling and marketing | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Operating income | 2.1 | 2.3 | 2.3 | 2.5 | 2.8 | 3.2 |
| Interest expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Income before tax | 2.0 | 2.3 | 2.0 | 2.0 | 2.4 | 2.8 |
| Income tax | 0.5 | 0.3 | 0.6 | 0.6 | 0.6 | 0.6 |
| Net income | 1.5 | 1.9 | 1.3 | 1.3 | 1.8 | 2.2 |
| Diluted EPS | $0.32 | $0.42 | $0.28 | $0.28 | $0.40 | $0.49 |
| Diluted shares (average) | 4,618m | 4,618m | 4,620m | 4,632m | 4,588m | 4,513m |
| EBITDA | — | — | — | 2.9 | 3.2 | 3.7 |
Compare with peers
- Viatris income statement
- Universe Pharmaceuticals Inc income statement
- Bausch Health Companies Inc. income statement
- Zoetis income statement
- Organon & Co. income statement
Head to head: HLN vs VTRSHLN vs UPCBHC vs HLNHLN vs ZTS
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies